|
|
|
|
LEADER |
03500nam a2200745Ia 4500 |
001 |
10.1002-jcla.23798 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23798
|
520 |
3 |
|
|a Background: Homocysteine assessment has been proposed as a potential predictive biomarker for the severity of COVID-19 infection. The purpose of this review was to analyze the correlation between the prevalence of MTHFR C677 T gene polymorphism and COVID-19 incidence and mortality worldwide. Methods: Data regarding MTHFR C677 T gene mutation were obtained from the interrogation of the Genome Aggregation Database (genomAD), which is publicly available from the web“https://gnomad.broadinstitute.org.” COVID-19 cases, including prevalence and mortality, were obtained from“https://www.worldometers.info/coronavirus” 27 August 2020. Results: There is a clear trend toward the worldwide prevalence of MTHFR 677 T and COVID-19 incidence and mortality. The prevalence of MTHFR 677 T allele in the Latino population, and the incidence and mortality for COVID-19 was higher for this ethnic group than that reported for most other populations globally. Statistical analysis showed a relatively strong correlation between C677 T and death from coronavirus. Conclusions: Genetic polymorphism of MTHFR C677 T may modulate the incidence and severity of COVID-19 pandemic infection. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a 5,10 methylenetetrahydrofolate reductase (FADH2)
|
650 |
0 |
4 |
|a allele
|
650 |
0 |
4 |
|a Alleles
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a C677 T mutation prevalence
|
650 |
0 |
4 |
|a C677T gene
|
650 |
0 |
4 |
|a coronavirus disease 2019
|
650 |
0 |
4 |
|a correlational study
|
650 |
0 |
4 |
|a COVID-19
|
650 |
0 |
4 |
|a COVID-19 vulnerability
|
650 |
0 |
4 |
|a disease predisposition
|
650 |
0 |
4 |
|a disease severity
|
650 |
0 |
4 |
|a disease transmission
|
650 |
0 |
4 |
|a enzymology
|
650 |
0 |
4 |
|a epidemiology
|
650 |
0 |
4 |
|a ethnic group
|
650 |
0 |
4 |
|a Ethnic Groups
|
650 |
0 |
4 |
|a gene
|
650 |
0 |
4 |
|a gene frequency
|
650 |
0 |
4 |
|a Gene Frequency
|
650 |
0 |
4 |
|a gene mutation
|
650 |
0 |
4 |
|a genetic correlation
|
650 |
0 |
4 |
|a genetic polymorphism
|
650 |
0 |
4 |
|a genetic predisposition
|
650 |
0 |
4 |
|a Genetic Predisposition to Disease
|
650 |
0 |
4 |
|a genetic variability
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a Hispanic
|
650 |
0 |
4 |
|a Homocysteine
|
650 |
0 |
4 |
|a homocysteine metabolism
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a incidence
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a methylenetetrahydrofolate reductase (NADPH2)
|
650 |
0 |
4 |
|a Methylenetetrahydrofolate Reductase (NADPH2)
|
650 |
0 |
4 |
|a mortality
|
650 |
0 |
4 |
|a mortality rate
|
650 |
0 |
4 |
|a MTHFR gene
|
650 |
0 |
4 |
|a predictive value
|
650 |
0 |
4 |
|a prevalence
|
650 |
0 |
4 |
|a prevalence
|
650 |
0 |
4 |
|a Prevalence
|
650 |
0 |
4 |
|a trend study
|
700 |
1 |
|
|a Iannella, R.
|e author
|
700 |
1 |
|
|a Kaleci, S.
|e author
|
700 |
1 |
|
|a Manfredini, M.
|e author
|
700 |
1 |
|
|a Oliva, G.
|e author
|
700 |
1 |
|
|a Ozben, T.
|e author
|
700 |
1 |
|
|a Pastorino, L.
|e author
|
700 |
1 |
|
|a Ponti, G.
|e author
|
700 |
1 |
|
|a Tomasi, A.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|